Wednesday, October 4, 2023
Wednesday, October 4, 2023

Contact: 561.316.3330

Neurovision Medical Products Receives Second Patent for Detection of Reversible Nerve Injury

NEUROVISION MEDICAL PRODUCTS, INC. announced that it has been granted United States Patent No. 10,517,493, making it the second patent related to the company’s nerve location platform, Nerveäna.

The Nerveäna system is designed to utilize the digital logic of NPI (Nerve Power Index) and gives surgeons the ability to collect and interpret data that detects nerve weakness before the onset of palsy during surgery. The technology allows surgeons to conveniently identify and avoid traction, stretching, or other insults that could lead to nerve damage. The ability to detect reversible nerve injury with the NPI algorithm can improve surgical outcomes for patients.

The NPI algorithm is an intuitive surgical tool that provides a real-time indication of the relative health and integrity of the nerve. A critical aspect of preventing irreversible nerve damage or vocal cord paralysis is the surgeon’s ability to identify and monitor at-risk motor nerves. With the unique algorithm, NMP has pioneered the use of data to expand the clinician’s awareness of nerve functionality intraoperatively. The NPI generates values corresponding to nerve strength within the dissecting process used to complete the surgery. Dr. James Lee Rea, CEO of NMP explains the distinct utilization of NPI:

“Unlike competitive platforms, the NPI requires no additional sensors and provides information by the same surgical instruments used in surgical maneuvers. A single NPI number, along with audio alerts, indicates the power of nerve and muscle response. The quality of conduction is audibly expressed by a two-tone system, with a higher-pitched tone occurring with an NPI >100, and a lower-pitched tone occurring with an NPI <100.”

NPI offers digital logic that can assist surgeons in their efforts to protect motor nerves and improve patient outcomes.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Centinel Spine’s prodisc ® Continues to Change Lives After Over 30 Years and 250,000 Total Disc Replacement Implantations

The prodisc lumbar and cervical technologies will be highlighted by Centinel Spine at the upcoming 2023 annual EUROSPINE meeting and congress in Frankfurt, Germany (October 4-6, 2023). The prodisc technology portfolio now includes four cervical and two lumbar devices—5 approved by the FDA—and has been validated with a reported reoperation rate of less than 1%.

Amber Implants Announces Start of Clinical Trial with VCFix® Spinal System

This first-in-human clinical trial will assess the safety and effectiveness of the VCFix® Spinal System implant for patients suffering from vertebral compression fractures. The implant is provided with a user-friendly, single-use sterile surgical kit, ensuring perfect traceability and reducing the risk of infection. 

RaySearch Deepens Collaboration with P-Cure

The expanded collaboration will enable users of the P-Cure proton therapy system to use RayStation and RayCare in a seamlessly integrated environment. The P-Cure system is a gantry-less seated proton system, designed to fit within linac vaults, that has recently been cleared by the FDA. It is used clinically by the Hadassah Medical Center in Jerusalem – the only proton facility in the Middle East – to treat CNS, head and neck, thoracic and pancreatic malignancies.

Edinburgh-based Med-tech Firm in MBO to Expand Into New Markets and Technologies

The acquisition will enable Novarum to build on its strong lateral flow test customer base and extend into adjacent markets. 

Biomic Sciences Issues Voluntary Nationwide Recall of ION* Sinus Support, ION* Biome Sinus, and Restore Sinus Spray Products Due to Microbial Contamination

Risk Statement: In the population most at risk, patients or individuals who recently underwent nasal or sinus surgery, there is a reasonable probability that the use of the affected product could potentially result in severe or life-threatening adverse events such as bacteremia or fungemia, invasive bacterial or fungal rhinosinusitis, or disseminated fungal infection. To date, Biomic Sciences has not received any reports of adverse events related to this product.

By using this website you agree to accept Medical Device News Magazine Privacy Policy